Debio-0123 is primarily investigated for its potential in oncology, specifically as a targeted therapy in cancer treatment. It functions as a selective inhibitor of certain tyrosine kinases involved in tumor growth and progression. Its application is particularly relevant in cancers driven by specific genetic mutations that lead to abnormal kinase activity. Due to its ability to cross the blood-brain barrier, Debio-0123 shows promise in treating central nervous system metastases, which are often challenging with conventional therapies. It is being studied in clinical trials for advanced solid tumors, especially non-small cell lung cancer and other malignancies with defined molecular targets. The compound's design aims to improve efficacy and reduce resistance compared to earlier generation inhibitors.